PPH Performance — VanEck Pharmaceutical ETF
Data updated: 2026-08-26
PPH returned +6.97% year to date and +27.14% over one year to Jun 2026. Annualised returns are +13.83% over 3 years and +10.55% over 5 years. Against its Health Care Equity category average the fund came out ahead over three years but behind over one: $100 invested three years ago grew to $147, against $138 for the category, and to $127 over one year, against $137. Volatility over the past three years was 13.81% a year. In the 12 months to Jun 2026 the fund took in a net $71.6M, and assets reached $879.46M.
PPH Growth of $100
What $100 invested in VanEck Pharmaceutical ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | PPH | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $127 | $137 |
| 3 years (Jul 2023 – Jun 2026) | $147 | $138 |
| 5 years (Jul 2021 – Jun 2026) | $165 | $121 |
| Since data start (Jul 2019 – Jun 2026) | $213 | $182 |
PPH Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +6.97% |
| 1 year | +27.14% |
| 3 years (annualised) | +13.83% |
| 5 years (annualised) | +10.55% |
PPH Annual Returns
Calendar-year total returns of VanEck Pharmaceutical ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +6.97% |
| 2025 | +21.93% |
| 2024 | +8.13% |
| 2023 | +6.89% |
| 2022 | +2.64% |
| 2021 | +18.28% |
| 2020 | +5.21% |
| 2019 (Jul–Dec) | +10.52% |
PPH Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +3.5% | +4.6% | −6.7% | −1.5% | +2.9% | +4.4% | — | — | — | — | — | — |
| 2025 | +3.1% | +5.3% | −2.7% | −1.1% | −1.7% | −0.1% | −5.1% | +7.1% | +1.6% | +2.8% | +10.8% | +0.9% |
| 2024 | +4.8% | +4.2% | +2.1% | −2.9% | +3.2% | +1.2% | +2.1% | +6.8% | −4.3% | −3.7% | −1.2% | −3.8% |
| 2023 | +0.8% | −3.5% | +2.6% | +2.5% | −4.2% | +4.3% | +2.5% | +1.8% | −2.5% | −5.2% | +4.3% | +4.0% |
| 2022 | −1.4% | −0.1% | +5.2% | −2.1% | +2.1% | −3.0% | +0.4% | −8.0% | −4.9% | +8.8% | +5.9% | +1.1% |
| 2021 | +2.9% | −1.0% | +2.3% | +1.5% | +3.7% | +1.1% | +2.9% | +1.6% | −4.4% | +3.8% | −4.9% | +8.1% |
| 2020 | +0.1% | −7.8% | −7.8% | +12.1% | +4.5% | −1.7% | +1.9% | +2.1% | −3.7% | −4.6% | +10.3% | +2.1% |
| 2019 | — | — | — | — | — | — | −1.6% | −1.9% | +1.0% | +4.7% | +4.9% | +3.4% |
PPH Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 13.81%
- 3-year Sharpe ratio: 0.68 (vs 4.5% risk-free rate)
- Best month: +10.84% (Nov 2025)
- Worst month: −6.68% (Mar 2026)
PPH Fund Flows
Monthly money in and out of VanEck Pharmaceutical ETF, from SEC Form N-PORT.
- 12-month net flow: $71.6M
- 12-month gross sales (incl. reinvestments): $2.2B
- Sales ÷ redemptions: 1.03×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $142.2M | $243.8M | −$101.6M |
| May 2026 | $51.5M | $102.1M | −$50.6M |
| Apr 2026 | $0 | $296.6M | −$296.6M |
| Mar 2026 | $162.6M | $97.6M | $65.0M |
| Feb 2026 | $225.1M | $147.1M | $78.0M |
| Jan 2026 | $120.8M | $262.0M | −$141.2M |
| Dec 2025 | $235.6M | $146.6M | $89.0M |
| Nov 2025 | $73.3M | $183.6M | −$110.3M |
| Oct 2025 | $859.5M | $231.9M | $627.6M |
| Sep 2025 | $97.4M | $186.1M | −$88.7M |
| Aug 2025 | $176.5M | $33.9M | $142.7M |
| Jul 2025 | $73.7M | $215.2M | −$141.6M |
PPH Assets Under Management
Net assets of VanEck Pharmaceutical ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $879.46M |
| 2026-03-31 | $1.29B |
| 2025-12-31 | $1.28B |
| 2025-09-30 | $545.51M |
| 2025-06-30 | $614.86M |
| 2025-03-31 | $668.74M |
| 2024-12-31 | $594.56M |
| 2024-09-30 | $721.76M |
| 2024-06-30 | $598.17M |
| 2024-03-31 | $543.21M |
| 2023-12-31 | $450.57M |
| 2023-09-30 | $430.04M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.